Página 7 dos resultados de 25922 itens digitais encontrados em 0.013 segundos

Participa??o das citocinas Interleucina-12, Interferon-?, Interleucina-4 e Interleucina-10 e investiga??o de polimorfismos nos genes do INF-? (IFNG+874) e da IL-10 (IL10-1082) na mal?ria causada por Plasmodium vivax

MEDINA, Tiago da Silva
Fonte: Universidade Federal do Pará Publicador: Universidade Federal do Pará
Tipo: Dissertação de Mestrado
Português
Relevância na Pesquisa
36.38%
A resposta imune na mal?ria ? complexa, e os mecanismos de ativa??o e regula??o de linf?citos T efetores e de mem?ria ainda s?o pouco compreendidos. No presente estudo, determinamos a concentra??o das citocinas Interferon-? (IFN-?), Interleucina-10 (IL-10), Interleucina-4 (IL-4) e Interleucina-12 (IL-12) no soro de indiv?duos infectados por Plasmodium vivax, investigamos os polimorfismos no gene do IFN-? (IFNG+874) e da IL-10 (IL10-1082) e analisamos a associa??o destes polimorfismos com a concentra??o das citocinas e com a densidade parasit?ria. A concentra??o das citocinas foi determinada por ELISA, e a genotipagem dos polimorfismos IFNG+874 e IL10-1082 foi realizada pelas t?cnicas de ASO-PCR e PCR-RFLP, respectivamente. Os indiv?duos infectados apresentaram n?veis s?ricos de IFN-? e IL-10 aumentados. A produ??o de IFN-? foi maior nos indiv?duos primoinfectados, por?m n?o foi associada com a redu??o da parasitemia. A produ??o de IL-10 foi alta e associada com altas parasitemias. As citocinas IL-4 e IL-12 n?o foram detectadas. As freq??ncias dos gen?tipos homozigoto mutante AA, heterozigoto AT e selvagem TT do gene do IFN-? foram 0,51, 0,39 e 0,10, respectivamente. As freq??ncias dos gen?tipos homozigoto mutante AA, heterozigoto AG e selvagem GG para IL10 foram 0...

Étude génétique et fonctionnelle des Interferon-producing Killer Dendritic Cells

Guimont-Desrochers, Fanny
Fonte: Université de Montréal Publicador: Université de Montréal
Tipo: Thèse ou Mémoire numérique / Electronic Thesis or Dissertation
Português
Relevância na Pesquisa
36.38%
L’idée qu’une cellule puisse effectuer la cytolyse de cellules transformées, comme une cellule Natural Killer (NK), tout en ayant la capacité de présenter des antigènes, comme une cellule dendritique (DC), peut sembler fantaisiste. Cependant, de telles cellules furent bel et bien identifiées chez la souris en 2006. Ces cellules, nommées Interferon-producing Killer Dendritic Cells (IKDC), furent l’objet d’une caractérisation extensive qui révéla leur énorme potentiel immunologique. La combinaison de fonctions associées à des cellules NK et à des DC a doté les IKDC d’un pouvoir antitumoral remarquable. D’ailleurs, il a été démontré que les IKDC sont plus efficaces que les cellules NK pour limiter la croissance tumorale. Ainsi, suite à leur découverte, les IKDC ont suscité beaucoup d’intérêt. Cependant, une controverse émergea sur la nature des IKDC. Plusieurs groupes indépendants tentèrent de reproduire les expériences attestant les fonctions de DC des IKDC, sans y parvenir. De plus, des études additionnelles révélèrent que les IKDC possèdent des similitudes très importantes avec les cellules NK. Ces observations ont mené la communauté scientifique à suggérer que les IKDC sont des cellules NK en état d’activation (aNK). Malgré cette controverse...

The interferon signaling pathway genes as biomarkers of hepatitis C virus disease progression and response to treatment

Helbig, K.; Beard, M.
Fonte: Future Medicine Ltd Publicador: Future Medicine Ltd
Tipo: Artigo de Revista Científica
Publicado em //2012 Português
Relevância na Pesquisa
36.38%
Hepatitis C virus is an ever-increasing worldwide health problem with over 350,000 individuals succumbing to hepatitis C virus-related liver diseases each year. The ability to determine the outcome of an acute-phase illness may be useful in terms of implementing treatment strategies; however, to date, the predictive associations in the literature have centered around candidate gene analysis. Much greater advancements have been made in describing biomarkers from the activation of the host innate immune response, such as the interferon system, for prediction of treatment outcome in chronic hepatitis C with the advent of genome-wide association studies. Recent times has seen a major breakthrough in the field with the description of the IL28B genotype as an independent association factor for pegylated IFN-α2b/ribavirin treatment response. The ability to couple this with other easily measured biomarkers such as the interferon-stimulated gene CXCL10, serum concentration may make this predictive marker set very useful in the clinical setting.; Karla J Helbig & Michael R Beard

Efficacy and tolerability of pegylated interferon-α-2a in chronic hepatitis B: a multicenter clinical experience; Efficacy and tolerability of pegylated interferon-alpha-2a in chronic hepatitis B: a multicenter clinical experience

Ratnam, D.; Dev, A.; Nguyen, T.; Sundararajan, V.; Harley, H.; Cheng, W.; Lee, A.; Rusli, F.; Chen, R.; Bell, S.; Pianko, S.; Sievert, W.
Fonte: Blackwell Publishing Asia Publicador: Blackwell Publishing Asia
Tipo: Artigo de Revista Científica
Publicado em //2012 Português
Relevância na Pesquisa
36.38%
BACKGROUND AND AIM: Pegylated interferon-α (PEG-IFN) provides potential advantages over nucleos(t)ide analogues in the treatment of chronic hepatitis B (CHB) given its finite course, durability and lack of drug resistance. Much of the evidence is derived from controlled studies and it is unclear whether these results can be replicated in an everyday, non-controlled setting. The aim of this study was to examine the efficacy and tolerability of PEG-IFN-α2A in CHB patients in a clinical setting. METHODS: Chronic hepatitis B patients treated with PEG-IFN-α2A (180µg/week, 48 weeks) at five tertiary hospitals were retrospectively identified. Baseline demographic and clinical data, on-treatment virological and serological responses and adverse events (AE) were recorded. Treatment outcomes were defined as alanine aminotransferase (ALT) normalization, hepatitis B virus DNA <351 IU/mL and hepatitis B e antigen (HBeAg) seroconversion. RESULTS: Sixty three HBeAg positive patients were identified (65% male, 80% born in Asia, 84% with viral loads > 6log IU/mL, 9.5% advanced fibrosis). Six months after therapy 46% achieved normalization of ALT, 16% had viral loads < 351 IU/mL and 32% achieved HBeAg seroconversion. 29 HBeAg negative patients were treated (75% male...

A chemokine-like viral protein enhances alpha interferon production by plasmacytoid dendritic cells but delays CD8⁺ T cell activation and impairs viral clearance; A chemokine-like viral protein enhances alpha interferon production by plasmacytoid dendritic cells but delays CD8(+) T cell activation and impairs viral clearance

Wikstrom, M.; Fleming, P.; Comerford, I.; McColl, S.; Andoniou, C.; Degli-Esposti, M.
Fonte: Amer Soc Microbiology Publicador: Amer Soc Microbiology
Tipo: Artigo de Revista Científica
Publicado em //2013 Português
Relevância na Pesquisa
36.38%
Murine cytomegalovirus encodes numerous proteins that act on a variety of pathways to modulate the innate and adaptive immune responses. Here, we demonstrate that a chemokine-like protein encoded by murine cytomegalovirus activates the early innate immune response and delays adaptive immunity, thereby impairing viral clearance. The protein, m131/129 (also known as MCK-2), is not required to establish infection in the spleen; however, a mutant virus lacking m131/129 was cleared more rapidly from this organ. In the absence of m131/129 expression, there was enhanced activation of dendritic cells (DC), and virus-specific CD8+ T cells were recruited into the immune response earlier. Viral mutants lacking m131/129 elicited weaker production of alpha interferon (IFN-α) at 40 h postinfection, indicating that this protein exerts its effects during early rounds of viral replication in the spleen. Furthermore, while wild-type and mutant viruses activated plasmacytoid dendritic cells (pDC) equally at this time, as measured by the upregulation of costimulatory molecules, the presence of m131/129 stimulated more pDC to secrete IFN-α, accounting for the stronger IFN-α response than from the wild-type virus. These data provide evidence for a novel immunomodulatory function of a viral chemokine and expose the multifunctionality of immune evasion proteins. In addition...

Production of a monoclonal antibody to human interferon-α (IFN-α) and its use to identify IFN-α-producing cells in virus infection in vivo; Production of a monoclonal antibody to human interferon-alpha (IFN-alpha) and its use to identify IFN-alpha-producing cells in virus infection in vivo

Jilbert, A.R.; Hertzog, P.J.; Burrell, C.J.; Gowans, E.J.; Linnane, A.W.; Marmion, B.P.
Fonte: Elsevier Publicador: Elsevier
Tipo: Artigo de Revista Científica
Publicado em //1986 Português
Relevância na Pesquisa
36.38%
A monoclonal antibody to human interferon-alpha (IFN-alpha) was produced using affinity-purified IFN-alpha, that reacted with recombinant human IFN-alpha 2, but not with IFN-alpha 1, IFN-alpha M1 or IFN-beta. Indirect immunofluorescence using this monoclonal (designated 6C3) and anti-IFN-alpha polyclonal antibodies identified cells expressing IFN-alpha. After Sendai virus induction of normal human buffy-coat cells the proportion of monocytes and lymphocytes expressing IFN-alpha rose progressively from 0% to 50% and 34% respectively, preceding peak IFN-alpha titres in the culture supernatants. Around 80-90% of polymorphs were IFN-alpha-positive using both antisera, with or without IFN induction, although very little IFN bioactivity was released to the supernatant of polymorph cultures after IFN induction. Sections of hepatitis B virus infected human liver tissue showed foci of IFN-alpha-positive infiltrating mononuclear cells and (to a lesser extent) fibroblasts in patients who had active cirrhosis and evidence of virus replication. These findings suggest that polymorphs constitutively express IFN-alpha 2 related antigenic activity, whose biological activity is at present unknown; and demonstrates the identification of IFN-alpha-expressing cells in sections of tissue undergoing natural virus infection.; Allison R. Jilbert...

Lung cancer is associated with decreased expression of perforin, granzyme B and interferon (IFN)-γ by infiltrating lung tissue T cells, natural killer (NK) T-like and NK cells; Lung cancer is associated with decreased expression of perforin, granzyme B and interferon (IFN)-gamma by infiltrating lung tissue T cells, natural killer (NK) T-like and NK cells

Hodge, G.; Barnawi, J.; Jurisevic, C.; Moffat, D.; Holmes, M.; Reynolds, P.N.; Jersmann, H.; Hodge, S.
Fonte: Wiley Publicador: Wiley
Tipo: Artigo de Revista Científica
Publicado em //2014 Português
Relevância na Pesquisa
36.38%
There is a limited understanding how of lung cancer cells evade cytotoxic attack. Previously, we have shown reduced production of the cytotoxic mediator granzyme B by CD8(+) T cells in lung cancer tissue. We hypothesized that lung cancer would be further associated with decreased production of granzyme B, perforin and proinflammatory cytokines by other cytotoxic lymphocytes, natural killer (NK) T-like and NK cells, and that this would result from soluble mediators released by the cancer cells. Lung cancer and non-cancer tissue from five patients was identified by experienced pathologists. Tumour necrosis factor (TNF)-α, interferon (IFN)-γ, granzyme B and perforin were measured in CD4 and CD8(+) T, NK T-like cells and NK cells by flow cytometry. Correlation between cancer stage and granzyme B was analysed retrospectively for 21 patients. The effects of soluble factors released by lung cancer cells on production of cytotoxic mediators and cytokines was assessed, and the role of prostaglandin E2 (PGE)2 /COX investigated using indomethacin inhibition. There were significantly decreased percentages of T, NK T-like and NK cells expressing perforin, TNF-α and IFN-γ in cancer versus non-cancer tissue, and of CD8(+) T cells and CD8(+) NK T-like cells expressing granzyme B (e.g. NK T-like cells: non-cancer 30% ± 7 versus cancer 6% ± 2·5). Cancer cells released soluble factors that inhibited granzyme B...

Early exposure of interferon-γ inhibits signal transducer and activator of transcription-6 signalling and nuclear factor κB activation in a short-term monocyte-derived dendritic cell culture promoting 'FAST' regulatory dendritic cells; Early exposure of interferon-gamma inhibits signal transducer and activator of transcription-6 signalling and nuclear factor kappaB activation in a short-term monocyte-derived dendritic cell culture promoting 'FAST' regulatory dendritic cells

Rojas-Canales, D.; Krishnan, R.; Jessup, C.; Coates, P.
Fonte: Blackwell Publishing Ltd Publicador: Blackwell Publishing Ltd
Tipo: Artigo de Revista Científica
Publicado em //2012 Português
Relevância na Pesquisa
36.38%
Early exposure of interferon-γ inhibits signal transducer and activator of transcription-6 signalling and nuclear factor κB activation in a short-term monocyte-derived dendritic cell culture promoting ‘FAST’ regulatory dendritic cellsInterferon (IFN)-γ is a cytokine with immunomodulatory properties, which has been shown previously to enhance the generation of tolerogenic dendritic cells (DC) when administered early ex vivo in 7-day monocyte-derived DC culture. To generate tolerogenic DC rapidly within 48 h, human monocytes were cultured for 24 h with interleukin (IL)-4 and granulocyte–macrophage colony-stimulating factor (GM-CSF) in the presence (IFN-γ-DC) or absence of IFN-γ (500 U/ml) (UT-DC). DC were matured for 24 h with TNF-α and prostaglandin E2 (PGE2). DC phenotype, signal transducer and activator of transcription-6 (STAT-6) phosphorylation and promotion of CD4+CD25+CD127neg/lowforkhead box P3 (FoxP3)hi T cells were analysed by flow cytometry. DC nuclear factor (NF)-κB transcription factor reticuloendotheliosis viral oncogene homologue B (RELB) and IL-12p70 protein expression were also determined. Phenotypically, IFN-γ-DC displayed reduced DC maturation marker CD83 by 62% and co-stimulation molecules CD80 (26%) and CD86 (8%). IFN-γ treatment of monocytes inhibited intracellular STAT6...

Interferon autoantibodies associated with AIRE deficiency decrease the expression of IFN-stimulated genes

Kisand, K.; Link, M.; Wolff, A.; Meager, A.; Tserel, L.; Org, T.; Murumagi, A.; Uibo, R.; Willcox, N.; Podkrajek, K.; Battelino, T.; Lobell, A.; Kampe, O.; Lima, K.; Meloni, A.; Ergun-Longmire, B.; Maclaren, N.; Perheentupa, J.; Krohn, K.; Scott, H.; et a
Fonte: Amer Soc Hematology Publicador: Amer Soc Hematology
Tipo: Artigo de Revista Científica
Publicado em //2008 Português
Relevância na Pesquisa
36.38%
Neutralizing autoantibodies to type I, but not type II, interferons (IFNs) are found at high titers in almost every patient with autoimmune polyendocrinopathy candidiasis ectodermal dystrophy (APECED), a disease caused by AIRE gene mutations that lead to defects in thymic T-cell selection. Combining genome-wide expression array with real time RT-PCR assays, we here demonstrate that antibodies against IFN-{alpha} cause highly significant down-regulation of interferon-stimulated gene expression in cells from APECED patients' blood by blocking their highly dilute endogenous IFNs. This down-regulation was lost progressively as these APECED cells matured in cultures without neutralizing autoantibodies. Most interestingly, a rare APECED patient with autoantibodies to IFN-{omega} but not IFN-{alpha} showed a marked increase in expression of the same interferon-stimulated genes. We also report unexpected increases in serum CXCL10 levels in APECED. Our results argue that the breakdown of tolerance to IFNs in AIRE deficiency is associated with impaired responses to them in thymus, and highlight APECED as another autoimmune disease with associated dysregulation of IFN activity.; Kai Kisand, ... Hamish S. Scott, et al.

Cryoglobulinemia in chronic hepatitis C: clinical aspects and response to treatment with interferon alpha and ribavirin

Parise,Edison Roberto; Oliveira,Ana Cláudia de; Ferraz,Maria Lúcia; Pereira,Aparecido Bernardo; Leite,Kátia Ramos
Fonte: Instituto de Medicina Tropical Publicador: Instituto de Medicina Tropical
Tipo: Artigo de Revista Científica Formato: text/html
Publicado em 01/04/2007 Português
Relevância na Pesquisa
36.38%
INTRODUCTION: The main extra-hepatic manifestation of hepatitis C is mixed cryoglobulinemia (MC). The aim of this study was to evaluate its prevalence among patients with chronic hepatitis C (CHC), to correlate its presence to host and virological variables and to the response to combined therapy with interferon-alpha and ribavirin. CASUISTIC AND METHODS: 202 CHC naive patients (136 with chronic hepatitis and 66 with cirrhosis) were consecutively evaluated for the presence of cryoglobulins. Cryoprecipitates were characterized by immunoelectrophoresis and classified according to the Brouet's criteria. RESULTS: The prevalence of MC was 27% (54/202), and 24% of them (13/54) showed major clinical manifestation of the disease. Even though type III MC was more frequent (78%), symptomatic MC was more common in type II MC. The presence of cirrhosis (RR = 2.073; IC95% = 1.029 - 4.179; p = 0.041), and age of the patients (RR = 1.035; IC95% = 1.008 - 1.062; p = 0.01) were independently associated with the presence of cryoglobulins. No relationship was found with viral load and genotype. 102 patients were treated with interferon alpha and ribavirin. Among these, 31 had MC. Sustained virological response (around 30%) was similar in patients with and without MC (p = 0.971). CONCLUSION: MC represents a prevalent complication in patients with CHC...

Suppression of interferon β gene transcription by inhibitors of bromodomain and extra-terminal (BET) family members

Malik, Nazma; Vollmer, Stefan; Nanda, Sambit Kumar; Lopez-Pelaez, Marta; Prescott, Alan; Gray, Nathanael; Cohen, Philip
Fonte: Portland Press Ltd. Publicador: Portland Press Ltd.
Tipo: Artigo de Revista Científica
Português
Relevância na Pesquisa
36.38%
PLK (Polo-like kinase) inhibitors, such as BI-2536, have been reported to suppress IFNB (encoding IFNβ, interferon β) gene transcription induced by ligands that activate TLR3 (Toll-like receptor 3) and TLR4. In the present study, we found that BI-2536 is likely to exert this effect by preventing the interaction of the transcription factors IRF3 (interferon-regulatory factor 3) and c-Jun with the IFNB promoter, but without affecting the TBK1 {TANK [TRAF (tumour-necrosis-factor-receptor-associated factor)-associated nuclear factor κB activator]-binding kinase 1}-catalysed phosphorylation of IRF3 at Ser396, the dimerization and nuclear translocation of IRF3 or the phosphorylation of c-Jun and ATF2 (activating transcription factor 2). Although BI-2536 inhibits few other kinases tested, it interacts with BET (bromodomain and extra-terminal) family members and displaces them from acetylated lysine residues on histones. We found that BET inhibitors that do not inhibit PLKs phenocopied the effect of BI-2536 on IFNB gene transcription. Similarly, BET inhibitors blocked the interaction of IRF5 with the IFNB promoter and the secretion of IFNβ induced by TLR7 or TLR9 ligands in the human plasmacytoid dendritic cell line GEN2.2, but without affecting the nuclear translocation of IRF5. We found that the BET family member BRD4 (bromodomain-containing protein 4) was associated with the IFNB promoter and that this interaction was enhanced by TLR3- or TLR4-ligation and prevented by BI-2536 and other BET inhibitors. Our results establish that BET family members are essential for TLR-stimulated IFNB gene transcription by permitting transcription factors to interact with the IFNB promoter. They also show that the interaction of the IFNB promoter with BRD4 is regulated by TLR ligation and that BI-2536 is likely to suppress IFNB gene transcription by targeting BET family members.

Combined pegylated interferon and ribavirin for the management of chronic hepatitis C in a prison setting

Sabbatani,Sergio; Giuliani,Ruggero; Manfredi,Roberto
Fonte: Brazilian Society of Infectious Diseases Publicador: Brazilian Society of Infectious Diseases
Tipo: Artigo de Revista Científica Formato: text/html
Publicado em 01/08/2006 Português
Relevância na Pesquisa
36.38%
The elevated frequency of chronic hepatitis C virus (HCV) infection found among prison inmates, and the availability of improved pharmacological cure for this potentially life-threatening disorder, make investigations conducted in this somewhat neglected area very relevant, since only a few, open-label experiences have been reported till now. In the metropolitan prison of Bologna (Italy), HCV seroprevalence was found to be over 31% in 2003, so that a pilot feasibility study based on treatment with pegylated interferon plus ribavirin was initiated, after careful counseling carried out by a joint commission of health care personnel of the correctional facility and infectious diseases consultants. Thirty-nine patients were enrolled, and despite expected dropouts due to difficulty in maintaining the same level of counseling pressure over time, and the particularly unfavorable climatic conditions during Summer 2003, a sustained virological response was obtained for 8 out of the 21 patients who remained evaluable after the first three month follow-up, although we need to take into account that a high percentage of subjects (67%) were selected for therapy due to their favorable HCV genotypes (types 2 and 3). Our preliminary experience shows that an intrinsically complicated therapy...

A recombinant vaccinia virus encoding the interferon-inducible T-cell alpha chemoattractant is attenuated in vivo

Hamilton, Nicholas H R; Mahalingam, Surendran; Banyer, Joanne; Ramshaw, Ian; Thomson, Scott
Fonte: Blackwell Publishing Ltd Publicador: Blackwell Publishing Ltd
Tipo: Artigo de Revista Científica
Português
Relevância na Pesquisa
36.38%
Murine interferon-inducible T-cell alpha chemoattractant (I-TAC) is a potent non-ELR CXC chemokine that predominantly attracts activated T lymphocytes, binds to the receptor CXCR3 and is induced by interferon-γ (IFN-γ). We analysed I-TAC expression by r

Induction of HIV-1-specific T-helper responses and type 1 cytokine secretion following therapeutic vaccination of macaques with a recombinant fowlpoxvirus co-expressing interferon-gamma

Dale, C Jane; Zhao, Anne; Jones, Stephen; Boyle, David B; Ramshaw, Ian; Kent, Stephen J
Fonte: Munksgaard International Publishers Publicador: Munksgaard International Publishers
Tipo: Artigo de Revista Científica
Português
Relevância na Pesquisa
36.38%
Preventive and/or therapeutic vaccines against Human Immunodeficiency Virus (HIV-1) are urgently required. Induction of cellular immunity is favoured since these responses correlate with control of HIV-1. Recombinant fowlpoxvirus (FPV) vaccines encoding both HIV-1 gag/pol and interferon-gamma (FPV gag/pol-IFNγ) were hypothesised to enhance HIV-specific cellular immunity and were further evaluated in macaques previously infected with HIV-1. A novel assay to detect IFNγ secretion following HIV antigen stimulation of whole blood was developed to further assess the safety and immunogenicity of the FPV gag/pol-IFNγ vaccine. Immunisation with FPV gag/pol-IFNγ safely enhanced HIV-specific IFNγ secretion following ex vivo stimulation of whole blood, greater than that observed following FPV gag/pol vaccination not co-expressing IFNγ. Both HIV-specific IFNγ-spot-forming cells by ELISPOT and CD69 expression by CD4+ lymphocytes were also enhanced following FPV gag/pol-IFNγ vaccination. Hence, the FPV-HIV vaccine co-expressing IFNγ stimulated HIV-specific T cell responses in macaques, and should be further evaluated as a therapeutic or preventive HIV vaccine. (C) Munksgaard, Copenhagen.

Tratamiento de hepatitis C en la insuficiencia renal crónica terminal en hemodiálisis con Interferón 2 b y ribavirina: A case report

Parodis López,Yanet; Pérez Rodríguez,Alexis; Arus Soler,Enrique; Gutiérrez,Francisco; Benítez Llanes,Orestes; Mármol Sóñora,Alexander
Fonte: Revista Cubana de Medicina Publicador: Revista Cubana de Medicina
Tipo: Artigo de Revista Científica Formato: text/html
Publicado em 01/08/2005 Português
Relevância na Pesquisa
36.38%
Se realizó la presentación clínica de un paciente de 32 años con antecedentes de salud hasta los 29 años de edad en que comienza a presentar una insuficiencia renal crónica terminal, se le aplicó tratamiento dialítico inmediatamente y 5 meses después se le diagnosticó una hepatitis C. Se decidió realizar trasplante renal donante vivo el cual no se puede efectuar dada la marcada citolisis existente, fue tratado inicialmente con interferón 2b durante un año sin negativizar el PCR por lo cual recibió posteriormente tratamiento combinado de interferón 2b y ribavirina (primer caso reportado en nuestro país en un paciente en hemodiálisis), se logró negativizar PCR, desapareció la citolisis y, finalmente, se logró el trasplante renal exitoso (donante vivo emparentado) 2 meses después de culminar el tratamiento. Se presentó la evolución bioquímica, hematológica y virológica con ambas terapéuticas.

Reporte de dos casos de linfadenitis supurada causada por bacilo de Calmette-Guerin tratados con interferón gamma recombinante

Abreu Suárez,Gladys; García García,Idrian; Fuentes Fernández,Gladys; Ramos Gómez,Thelvia I.; Martínez Grau,Isabel; González Méndez,Lidia; López Saura,Pedro A.
Fonte: Revista Cubana de Pediatría Publicador: Revista Cubana de Pediatría
Tipo: Artigo de Revista Científica Formato: text/html
Publicado em 01/09/2008 Português
Relevância na Pesquisa
36.38%
La linfadenitis supurada es una complicación poco frecuente que sigue a la vacunación con bacilo de Calmette-Guerin. Se describen los casos de dos niños con reacciones adversas graves inducidas por esta vacuna, en ambos casos, linfadenitis regional supurada y abscedada, un mes después de nacidos. Después de cursos infructuosos de cirugía y quimioterapia, ambos recibieron interferón gamma recombinante por vía intramuscular, en una dosis inicial de 50 000 UI/kg (máximo: 1 000 000 UI), diariamente durante las primeras 4 semanas, y se disminuyó luego la frecuencia de administración. Esta citoquina fue bien tolerada, solo se presentaron complicaciones con fiebre, que fueron controladas bien con antipiréticos. El interferón gamma recombinante puede constituir una nueva y efectiva alternativa terapéutica para el tratamiento de la linfadenitis supurada causada por este bacilo.

Aplicación Intralesional del Interferón alfa 2bHr cubano (Heberon Alfa R®) en el tratamiento de las verrugas genitales

Baladrón Castrillo,Idania; Barbón Gassó,Zaida; Solares Asteasuainzarra,Ana Margarita; Valenzuela Silva,Carmen; García Iglesias,Elizeth; Martínez Martínez-Pinillo,Angela
Fonte: Revista Cubana de Obstetricia y Ginecología Publicador: Revista Cubana de Obstetricia y Ginecología
Tipo: Artigo de Revista Científica Formato: text/html
Publicado em 01/06/2012 Português
Relevância na Pesquisa
36.38%
Introducción: la condilomatosis genital es la expresión clínica más frecuente de del virus del papiloma humano. De las alternativas de tratamiento existentes, no hay una de elección y absolutamente eficaz. Objetivo: describir la seguridad y el efecto del Interferón alfa recombinante, en el tratamiento de las verrugas genitales. Métodos: se incluyeron 216 mujeres y 111 hombres en un estudio cuasiexperimental. El producto se aplicó en la base de las verrugas a la dosis de 10 millones de unidades internacionales, semanalmente durante 8-16 semanas. Los pacientes fueron atendidos en el Hospital "Ramón González Coro" de La Habana de marzo del 2009 a junio del 2011. Se reportaron los eventos adversos en cada aplicación, estimándose su distribución de frecuencias. Se evaluó la respuesta objetiva de acuerdo al porcentaje de reducción de la sumatoria de los dímetros mayores a las 4, 8 y 16 semanas después de la aplicación. La recurrencia se evaluó a los 24 meses mediante la curva de Kaplan-Meier. Resultados: se observó respuesta al tratamiento en el 81,5 % de los pacientes. Más del 60 % tuvieron respuesta completa, de los cuales solo el 11,1% resultaron recurrentes. Los eventos adversos más frecuentes fueron: fiebre, cefalea y escalofríos de intensidad leve o moderada. Conclusiones: la aplicación perilesional de interferón puede considerarse una alternativa segura y eficaz en el tratamiento de las verrugas genitales.

Interferón alfa 2b recombinante más ribavirina en el tratamiento de la hepatitis crónica C

Sánchez Rodríguez,Yoan Antonio; Arús Soler,Enrique; Grá Oramas,Bienvenido; López Saura,Pedro; Nodarse Cuní,Hugo
Fonte: Revista Cubana de Medicina Publicador: Revista Cubana de Medicina
Tipo: Artigo de Revista Científica Formato: text/html
Publicado em 01/06/2010 Português
Relevância na Pesquisa
36.38%
El virus de la hepatitis C se ha convertido en la causa principal de hepatitis crónica, cirrosis hepática, hepatocarcinoma, y trasplante de hígado a nivel mundial. OBJETIVO: El presente estudio estuvo dirigido a determinar la evolución virológica, bioquímica e histológica de los pacientes con hepatitis crónica C bajo terapia combinada Interferón a 2b recombinante más ribavirina e identifica los principales factores asociados a las tasas obtenidas de respuesta virológica sostenida. MÉTODOS: Ensayo clínico-terapéutico fase IV, abierto, no controlado y multicéntrico rectorado por el Instituto de Gastroenterología y el Centro de Ingeniería Genética y Biotecnología en el período comprendido de mayo de 2001 a mayo de 2006. La muestra estuvo conformada por 122 pacientes con hepatitis crónica C que cumplieron con criterios de inclusión y exclusión predeterminados. Se utilizó interferón a 2b recombinante (3 millones de unidades 3 veces por semana) más ribavirina (1 000 o 1 200 mg diarios en dependencia del peso corporal) durante 48 sem. RESULTADOS: Se obtuvo una tasa de respuesta virológica y bioquímica sostenida a la semana 72 de 32,8 y 50,8 % respectivamente. Un 41,3 % del total de pacientes experimentó mejoría histológica a expensas de la reducción de la fibrosis y pocos cambios en la inflamación. CONCLUSIONES: Teniendo en cuenta la tasa de respuesta global obtenida...

Establecimiento de un material de referencia para interferón gamma humano recombinante

Vega,Maribel; Valderrama,Susset; Moya,Galina; Ferrero,Joel; Castiñeira,Mirta; Quintana,Marisel
Fonte: Revista Cubana de Farmacia Publicador: Revista Cubana de Farmacia
Tipo: Artigo de Revista Científica Formato: text/html
Publicado em 01/08/2005 Português
Relevância na Pesquisa
36.38%
Se caracterizó el lote de interferón gamma utilizado como material de referencia por diferentes técnicas analíticas y se demostró mediante los diferentes análisis de varianza realizados para cada una de las técnicas ensayadas, que el lote cumple con lo aceptado para ser usado como material de referencia. El estudio de homogeneidad realizado por la técnica de cromatografía líquida de alta eficacia en fase reversa demostró que el material de referencia posee el grado de homogeneidad requerido para su uso. El lote es estable por 2 años a - 70 °C, según estudios previos realizados a los lotes de producción de materia prima activa de interferón gamma humano recombinante.

Experiencia con las reacciones adversas asociadas con el interferón alfa 2b recombinante en hematología

Brito Pascual,Idalmis; Betancourt Rodríguez,Blas Yamir; Valenzuela Silva,Carmen; López Saura,Pedro
Fonte: Revista Cubana de Farmacia Publicador: Revista Cubana de Farmacia
Tipo: Artigo de Revista Científica Formato: text/html
Publicado em 01/08/2005 Português
Relevância na Pesquisa
36.38%
El interferón alfa 2b es una citoquina con actividad antiviral, antiproliferativa e inmunomoduladora que ha demostrado ser eficaz para el tratamiento de enfermedades virales y neoplásicas. El presente trabajo se realizó con el propósito de describir la frecuencia de las reacciones adversas asociada con la administración de Heberon alfa R (interferón alfa 2b recombinante) en enfermedades hematológicas. Se analizaron las características de base de los pacientes, así como la frecuencia, intensidad y relación de causalidad de los eventos reportados. Los eventos adversos más frecuentes fueron las manifestaciones del síndrome gripal que incluyó fiebre, escalofrío, astenia, mialgias, anorexia y cefalea. Estas manifestaciones son transitorias y responden al tratamiento con antiinflamatorios no esteroideos. La mayoría de los eventos fueron de intensidad leve a moderada y no requirieron la suspensión del tratamiento. En conclusión, el Heberon alfa R es un fármaco relativamente seguro para el tratamiento de trastornos hematológicos